What is the total market value of Non Invasive Prenatal Testing Market report?


NIPT tests can be performed in patients between 10 and 20 weeks of the gestation period. These tests require the extraction of fetal DNA from maternal blood to determine chromosomal abnormalities.

.

Non-Invasive Prenatal Testing (NIPT) Market-By Region

Expected Revenue Growth:

[144 Pages Report] The global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690

What This Report Will Provide?

The study involved four major activities in estimating the current size of the global non-invasive prenatal testing market. Exhaustive secondary research was done to collect information on the market, its peer markets, and its parent market.

The next step was to validate these findings, assumptions, and sizing values with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size.

Major Growth Boosters:

The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, the launch of new and advanced NIPT products, and increasing maternal age (growth in the risk of chromosomal abnormalities in babies).

Regional Growth Analysis:

North America dominated the market, followed by Europe. The large share of this market can primarily be attributed to the strong economies in the US and Canada, which have allowed for significant investments in technology in this region. Growth in the North American market is supported by the presence of a better reimbursement structure and a favorable funding scenario for research activities, rising awareness about NIPT, and the increasing demand for the early detection of birth defects in this region.

Key Market Players

The prominent players in the market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), BGI (China), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), and Yourgene Health (UK)

Recent Developments

  • BGI and Eluthia (Germany) launched the NIFTY test (non-invasive prenatal test), under the brand name PreviaTest in Germany.
  • Illumina expanded its NIPT platform with the launch of VeriSeq NIPT Solution v2.
  • Illumina and Pacific Biosciences signed an agreement for Illumina to acquire Pacific Biosciences. This acquisition will allow Illumina to strengthen its sequencing solutions platform with accurate long-read sequencing capabilities.

Key Questions Addressed by the Report

  1. Where will all these developments take the industry in the mid to long-term?
  2. What types of annual and multi-year partnerships are NIPT product and service companies exploring?
  3. Which are the key players in the market and how intense is the competition?
  4. Which are the recent contracts and agreements key players have signed?
  5. What are the recent trends affecting NIPT product and service providers?

Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=145607690

Reacties